Prática challenge of the management of covid-19 in patients with obesity

Obesity is a condition associated with worse outcomes of patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is linked to endocrine and immunological dysfunction, making the patient more vulnerable to the disease caused by the virus. Considering that the pathophysiological mechanisms involved in coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 are still unclear, the search for various drugs for the treatment or prevention of the disease is still in progress. Therefore, it is essential to review the mechanisms of action of drugs on severe COVID-19 and their pharmacological interaction with obesity.